Items tagged with Vaccines

BCG vaccine leads to long-term improvement in blood sugar levels in type 1 diabetes patients (post)

Long-term follow-up of participants in clinical trials of a generic vaccine to reverse advanced type 1 diabetes finds significant clinical benefits, including restoration of near-normal blood sugar levels. Three years after receiving two administrations of the bacillus Calmette-Guérin (BCG) vaccine four weeks apart, all members of a group of adults with longstanding type 1 diabetes showed an improvement in HbA1c to near normal levels – improvement that persisted for the following five years. The study from a Massachusetts General Hospital (MGH) research team – published in npj Vaccines – also reports that the effects of BCG vaccine on blood sugar control appear to depend on a totally novel metabolic mechanism that increases cellular consumption of glucose.

New England Journal of Medicine publishes final results from innovative Phase 2 study showing vaccines can reduce rate of sustained TB infections in adolescents at high risk (post)

Trial offers hope for new revaccination strategies with Bacille Calmette-Guerin (BCG) against TB, the world’s leading infectious disease killer.

Effective TB, HIV and malaria vaccines missing from drug development pipeline (post)

Many of the vaccines critically needed to fight some of the world’s most prevalent infectious diseases are not likely to be developed, a new analysis of current candidates in the research and development pipeline has found.

The TB Vaccine Development Pathway – a new tool for the TB vaccine community (post)

In the effort to eradicate tuberculosis as one of the world’s most deadly diseases, novel TB vaccines will be an important part of the solution. There is a pipeline of new TB vaccines that requires a global and comprehensive coordination of efforts with defined stages of development and criteria for progression of individual vaccine candidates.

GSK candidate vaccine helps prevent active pulmonary TB in HIV negative adults in phase II study (post)

Publication of primary results in the New England Journal of Medicine shows positive impact of innovative vaccine technology in clinical trial conducted in tuberculosis endemic regions.

IAVI acquires Aeras TB vaccine clinical programs and assets (post)

Data from two Phase II clinical trials conducted by Aeras and partners indicate promise for future of TB vaccine development.

First promising TB vaccine candidate in 100 years needs more resources, researchers say (post)

THE HAGUE, Netherlands, October 25, 2018 – When the Ebola outbreak hit West Africa in 2014 and took more than 11,000 lives in two years, public and private organizations mobilized the development of a vaccine in a year and a half. That vaccine now is being used to control the current outbreak in the Democratic Republic of Congo.

(post with image)

Novel vaccine trial design aims to answer key TB questions (post with simple image)

Prevention of infection study underway in South Africa.

The Lancet journals: World TB Day media alert (post with simple image)

For World TB Day 2014, The Lancet group publishes a Series of papers to highlight the need for global collaboration to diagnose, treat, and cure people with tuberculosis.

Page 11 of 13 · Total posts: 0

←First 10 11 12 Last→